Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Once melanomas have progressed with acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major challenge. We therefore examined the therapy phase before acquired resistance had developed and discovered the melanoma survival oncogene MIT...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer cell Vol. 29; no. 3; p. 270
Main Authors:	Smith, Michael P, Brunton, Holly, Rowling, Emily J, Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L, Girotti, Maria R, Marais, Richard, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Flaherty, Keith T, Cooper, Zachary A, Wargo, Jennifer A, Wellbrock, Claudia
Format:	Journal Article
Language:	English
Published:	United States 14.03.2016
Subjects:	Cell Line, Tumor Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Drug Tolerance - genetics GTP Phosphohydrolases - genetics HIV Protease Inhibitors - pharmacology Humans Melanoma - drug therapy Melanoma - genetics Membrane Proteins - genetics Mitogen-Activated Protein Kinases - metabolism Mutation - drug effects Mutation - genetics Nelfinavir - pharmacology Paired Box Transcription Factors - genetics PAX3 Transcription Factor Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - genetics Up-Regulation - drug effects Up-Regulation - genetics
ISSN:	1878-3686, 1878-3686
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!